Drug Approval | November 26, 2021
Aadi Bioscience secures U.S FDA approval of its first product Fyarro
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
It is estimated that one-third of our country’s population has some form of these disorders
Subscribe To Our Newsletter & Stay Updated
